Targeting Biology in Non-Hodgkin Lymphoma

Chemotherapy nonspecifically affects all cells undergoing DNA replication and has severe side effects. Understanding of the biology of non-Hodgkin lymphomas has led to development of drugs that target specific lymphoma cell functions and tumor microenvironment. Targeted agents used in combination wi...

Full description

Saved in:
Bibliographic Details
Published inHematology/oncology clinics of North America Vol. 33; no. 4; p. 727
Main Authors Narkhede, Mayur, Yazdy, Maryam Sarraf, Cheson, Bruce D
Format Journal Article
LanguageEnglish
Published United States 01.08.2019
Subjects
Non-Hodgkin lymphoma
Monoclonal antibodies
Intracellular oncogenic pathways
Targeted agents
Online AccessGet more information

Cover

More Information
Summary:Chemotherapy nonspecifically affects all cells undergoing DNA replication and has severe side effects. Understanding of the biology of non-Hodgkin lymphomas has led to development of drugs that target specific lymphoma cell functions and tumor microenvironment. Targeted agents used in combination with chemotherapy pave the way to a chemotherapy-free world. These drugs target multiple oncogenic pathways and modulate the immune system, with better outcomes. Such combinations should be administered only in clinical trials. Incorporating studies of the biology and genetics of these tumors into therapeutic studies may lead to a chemotherapy-free world with improved outcomes and reduced toxicities.
ISSN:1558-1977
DOI:10.1016/j.hoc.2019.03.006